Elan has sold the US marketing rights to its anti-epileptic drug for $130 million as part of its strategy to focus on developing drugs for the treatment of neurologically related illnesses.
Elan sold the rights to Zonergan to Eisai and may earn future deferred payments of up to $110 million if the drug wins marketing approval in Europe.
Elan will continue to manufacture Zonegran for Eisai which will contribute contract manufacturing revenue.
